Documenting the immune response in patients with COVID-19-induced acute respiratory distress syndrome

Front Cell Dev Biol. 2023 Jun 9:11:1207960. doi: 10.3389/fcell.2023.1207960. eCollection 2023.

Abstract

Introduction: Coronavirus disease 2019 (COVID-19) can lead to acute respiratory distress syndrome (ARDS) and life-threatening multi-organ failure with increased levels of inflammatory mediators and viral load; however, little is known about its pathophysiology. Methods: To better understand the cellular status of COVID-19-induced ARDS, we performed single-cell RNA sequencing on peripheral blood samples from patients with COVID-19-induced ARDS. Single-cell RNA sequencing combined with bioinformatics analysis was used to study dynamic changes in cell composition and transcriptional profiles. Results: The single-cell RNA sequencing data revealed significant phenotypic differences between patients with COVID-19-induced ARDS and controls, mainly in monocytes, and CD8+ T and B cells. B-cell and monocyte abundances were significant in COVID-19-induced ARDS patients compared to controls, while CD8+ T cells were depleted. These data suggest that there is an imbalance between lymphocytes and monocytes in the blood of COVID-19-induced ARDS patients. In addition, cytokine interactions between T cells, monocytes and B cells are enhanced as evidenced by the intercellular communication analysis. In particular, T cell subsets target receptors on other cells via CCL5 and may play an important role in patients with COVID-19-induced ARDS. Conclusion: Our analysis suggested that a dysregulated adaptive immune response exists in patients with COVID-19-induced ARDS. Overall, we provided a cellular picture of the peripheral immune response in patients with COVID-19-induced ARDS.

Keywords: COVID-19; acute respiratory distress syndrome; dysregulated immune response; immune cells; single-cell RNA sequencing.

Grants and funding

This study was supported by the Key Research and Development Program of Guangxi (GuiKe AB22080088), the National Natural Science Foundation of China (82060022 and 81960343), Guangxi Natural Science Foundation (2023GXNSFDA026023 and 2021GXNSFBA196017), the High-level Medical Expert Training Program of Guangxi “139”Plan Funding (G202003010 and G201903027) and the Guangxi Health Commission key Laboratory of Emergency and Critical Medicine (The Second Affiliated Hospital of Guangxi Medical University).